We are live on
!
Find out more
Calamos Advisors Portfolio holdings
AUM
$28.2B
1-Year Est. Return
21.78%
This Fund
S&P 500
This Quarter
Est. Return
+17.1%
1 Year Est. Return
+21.78%
3 Year Est. Return
+69.57%
5 Year Est. Return
+92%
10 Year Est. Return
+282.63%
AUM
$14.1B
AUM Growth
+$1.4B
(+11%)
Cap. Flow
-$4.28B
Cap. Flow
% of AUM
-30.25%
Top 10 Holdings %
Top 10 Hldgs %
20.4%
Holding
803
New
108
Increased
91
Reduced
295
Closed
98
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BSX.PRA
Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A
BSX.PRA
|
+$61M |
| 2 |
RTX Corp
RTX
|
+$38.2M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$15.5M |
| 4 |
Delta Air Lines
DAL
|
+$14.5M |
| 5 |
SWT
Stanley Black & Decker, Inc.
SWT
|
+$13.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$578M |
| 2 |
AGN
Allergan plc
AGN
|
+$67M |
| 3 |
BDXA
Becton, Dickinson and Company Depositary Shares, each Representing a 1/20th Interest in a Share of 6
BDXA
|
+$51.1M |
| 4 |
Alibaba
BABA
|
+$46.8M |
| 5 |
lululemon athletica
LULU
|
+$42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.91% |
| 2 | Healthcare | 8.15% |
| 3 | Consumer Discretionary | 7.49% |
| 4 | Financials | 7.2% |
| 5 | Communication Services | 5.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
501
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $651K | ﹤0.01% |
+11,713
| New | +$501K |
|
502
Churchill Downs
CHDN
$6.22B
| $648K | ﹤0.01% |
+9,734
| New | +$554K |
|
503
NIO
NIO
$11.7B
| $639K | ﹤0.01% |
+82,800
| New | +$364K |
|
504
Exagen
XGN
$108M
| $631K | ﹤0.01% |
50,794
-68,277
| -57% | -$924K |
|
505
Karyopharm Therapeutics
KPTI
$161M
| $607K | ﹤0.01% |
+2,136
| New | +$632K |
|
506
Zai Lab
ZLAB
$2.1B
| $607K | ﹤0.01% |
+7,390
| New | +$500K |
|
507
EPAM Systems
EPAM
$5.25B
| $606K | ﹤0.01% |
2,406
-482
| -17% | -$106K |
|
508
Uber
UBER
$144B
| $569K | ﹤0.01% |
+18,300
| New | +$570K |
|
|
MNTA
509
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $547K | ﹤0.01% |
+16,424
| New | +$523K |
|
510
Tractor Supply
TSCO
$16.5B
| $527K | ﹤0.01% |
+20,000
| New | +$437K |
|
511
iRhythm Holdings
IRTC
$3.86B
| $513K | ﹤0.01% |
+4,428
| New | +$488K |
|
512
Tidewater
TDW
$3.71B
| $484K | ﹤0.01% |
86,574
| – | – |
|
513
iShares Russell Mid-Cap ETF
IWR
$56.5B
| $472K | ﹤0.01% |
8,800
+300
| +4% | +$15K |
|
514
Roku
ROKU
$21.3B
| $460K | ﹤0.01% |
+3,950
| New | +$452K |
|
|
LUNA
515
DELISTED
Luna Innovations Incorporated
LUNA
| $432K | ﹤0.01% |
74,047
-175,047
| -70% | -$1.14M |
|
516
KORU Medical Systems
KRMD
$184M
| $427K | ﹤0.01% |
+47,524
| New | +$480K |
|
517
Schwab US Mid-Cap ETF
SCHM
$14.5B
| $389K | ﹤0.01% |
22,200
-3,561
| -14% | -$58K |
|
518
Newell Brands
NWL
$2.24B
| $278K | ﹤0.01% |
17,525
| – | – |
|
519
iShares Russell Top 200 ETF
IWL
$2.16B
| $267K | ﹤0.01% |
+3,600
| New | +$252K |
|
520
Devon Energy
DVN
$49.2B
| $266K | ﹤0.01% |
23,500
| – | – |
|
521
Vanguard Short-Term Bond ETF
BSV
$44.7B
| $248K | ﹤0.01% |
+2,987
| New | +$247K |
|
|
522
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $248K | ﹤0.01% |
803
-1,975,352
| -100% | -$578M |
|
523
Pultegroup
PHM
$25.7B
| $245K | ﹤0.01% |
+7,200
| New | +$216K |
|
524
Transocean
RIG
$5.52B
| $216K | ﹤0.01% |
117,879
| – | – |
|
|
GLOG
525
DELISTED
GASLOG LTD
GLOG
| $148K | ﹤0.01% |
52,725
| – | – |
|
Similar funds
PCH
N
TWC
FDCDDQ
NA
Calamos Advisors's Q2 2020 Portfolio in Review
As of Q2 2020, Calamos Advisors held 803 positions worth $14.1B, up 11% from $12.7B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Calamos Advisors withdrew a net $4.28B in Q2 2020, closing 98 positions and reducing 295 holdings. Its most notable exit was Allergan plc, an estimated $67M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Calamos Advisors opened a new position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A worth $59.7M.
- Calamos Advisors's largest Q2 2020 buy was Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A: 569,916 shares worth $59.7M.
- Calamos Advisors added most to RTX Corp in Q2 2020, an estimated $38.2M increase.
- Calamos Advisors's biggest Q2 2020 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $578M.
- Calamos Advisors fully exited Allergan plc in Q2 2020, selling an estimated $67M.
- Calamos Advisors's ten largest holdings make up 20% of its $14.1B portfolio in Q2 2020.
- Calamos Advisors opened 108 new positions and closed 98 in Q2 2020.
- Calamos Advisors's portfolio value rose 11% quarter-over-quarter to $14.1B.
Based on Calamos Advisors's 13F filing for Q2 2020, filed 27 Jul 2020.